Figure 7.

Sitravatinib combined with PD-L1 antibody increases ferroptosis and reduces MDSC infiltration in HCC microenvironment

(A and B) (A) T-SNE plot of tumor-infiltrating leukocytes overlaid with color-coded clusters and the frequency of clusters of the indicated immune cell subsets, including CD3⁺ T cells, CD8⁺ T cells, IFNγ⁺CD8⁺ T cells, CD4⁺ T cells, CD11b⁺ cells, and MDSCs in Res1-6 strains treated with IgG, sitravatinib, anti-PD-L1, or their combination and (B) the statistical analysis.

(C) Western blot analysis of p-MerTK, MerTK, SLC7A11, and β-actin expression in different groups.

(D) The representative imagines of IHC staining of p-MerTK, MerTK, and Ki-67 from subcutaneous tumors treated with IgG, sitravatinib, anti-PD-L1 or their combination. Scale bar: 100 μm.

(E–H) In subcutaneous xenograft mouse model, the statistical analysis of relative lipid ROS and MDA content in Res1-6 and Res-CA1 strains treated with IgG, sitravatinib, anti-PD-L1, or their combination.

All results are shown as mean ± SEM (n = 5). One- or two-way ANOVA was used to analyze the data; ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗p < 0.001.